Ackman: Valeant's main problem is PR, not fraud

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. TSLA
9. BRZE
10. GOOGL

Go back to Ackman: Valeant's main problem is PR, not fraud

Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages

October 30, 2015 12:57 PM EDT

The bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.

This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More

Valeant Pharma (VRX) falls below $100 again

October 30, 2015 11:58 AM EDT

Valeant Pharma (NYSE: VRX) falls below $100 again

... More

Bill Ackman said their average cost on Valeant Pharma (VRX) is $186

October 30, 2015 11:11 AM EDT

On Valeant Pharma (NYSE: VRX) call, Bill Ackman said their average cost is $186

... More